Technical Director of Cell Therapies Facility

Moffitt Cancer Center

Moffitt Cancer Center (MCC), an NCI-designated comprehensive cancer center in the state of Florida, and the #11 ranked Best Hospitals for Cancer on U.S. News & World Report, is seeking a visionary leader who will serve as the Technical Director of the Cell Therapies Facility (CTF), focused on the development and application of cell therapies across the spectrum of cancer care and research. MCC is seeking a leader in the field of cellular therapies who can leverage existing strengths at MCC to go along with world-renowned oncologists, immunologists, basic scientists, epidemiologists and health outcomes researchers, data scientists and machine learning experts, and other top-rated scientists, all to further Moffitt's mission to prevent and cure cancer care. This position offers an exciting opportunity to build upon Moffitt's significant cell therapies infrastructure, accelerating scientific discovery and translation to the clinic. Moffitt's size, its singular focus on cancer, and its close interaction and outreach with academic partners and caregivers throughout the state, nation, and world all contribute to the rich, collegial, and collaborative environment required to conduct outstanding clinical care and translational cancer research.

MCC includes a 206-bed hospital, three ambulatory care facilities, a 36-bed blood and marrow transplant program, 20 state-of-the-art operating suites, a 30-bed intensive care unit, a high-volume screening program, and a basic science research facility. The Moffitt Research Institute located on the main campus is comprised of approximately 160 Principal Investigators, 58 laboratories, and 306,000 square feet of research space. MCC provides care to over 400,000 outpatients annually, including the largest blood and bone marrow transplant program in the southeast.

The CTF is located on Moffitt's McKinley Campus (MKC), approximately one mile from the MCC main campus. MKC was opened in 2015 and due to its rapid success, there are plans for expansion already underway. MKC includes a six-story, 207,000 square-foot facility that provides a long list of patient care options ranging from skin cancer treatment to survivorship services to a breast cancer clinic, molecular services, and diagnostic imaging. In June 2020, MCC broke ground on a new $400 million hospital to be located on the 20-acre McKinley Campus, which will be a 10-story, 498,000 square-foot facility, opened in order to expand MCC's capacity for inpatient hospital care. The new hospital is planned to open in July 2023. The first phase of the hospital will include 128 inpatient beds, 19 operating rooms, 72 perioperative rooms, three MRI scanners, three CT scanners and two nuclear cameras, radiology, endoscopy, imaging, conference space, and education and research space. The hospital will have the capacity to expand to 400 beds.

The CTF is in a newly constructed state-of-the-art 8,200 square foot GMP compliant physical plant and is directly affiliated with MCC's 36-bed blood and marrow transplant unit, the transplant unit at MCC's pediatric affiliate institution, and MCC's dedicated clinical research unit. The CTF is also a designated core facility supported by Moffitt's NCI support grant, as well as one of five NHLBI designated PACT sites nationally.

The incoming Director will be responsible for all aspects of production of cellular therapeutics at Moffitt as well as activities associated with its NHLBI funded contracts. The Director will also be expected to develop additional cellular therapeutics as the active research programs in transplantation and immunotherapy may require. Products currently under production include blood and marrow transplant

products, CAR-T and ex vivo expanded tumor infiltrating lymphocytes (TIL) for adoptive transfer, experimental anti-tumor vaccines built on both tumor cell lines and autologous dendritic cells, and culture expanded Tregs for modulation of graft versus host disease.

The ideal candidate must have demonstrated education and experience in the areas of: hematopoietic progenitor cell transplantation principles and practices; documented experience in cell processing and cryopreservation methods; apheresis technology and practice; cell culture methods for preparation of therapeutic cells; cell separation technology; master process record and batch process record development and maintenance, including requirements for electronic record keeping systems; and regulation and accreditation requirements for cell processing facilities, in particular foundation for accreditation of cellular therapy (FACT), GTP (21CFR1271 and GMP (21CFR211, 21CFR610). The successful candidate will also have a proven track record in obtaining peer-reviewed support for research or educational activities.

In addition to oversight of preparation and analysis of all cellular therapeutics, the Director is responsible for continual updating of production methods consistent with best practices reported in the scientific literature. The Director will work closely with the CTF's assigned Quality Director and the Institutional Office of Regulatory Affairs to maintain state of the art quality management. The Director will be expected to participate in the renewal cycles of Moffitt's NCI P30 cancer center support grant, and for assisting in the preparation of individual investigator research grants and manuscripts.

MCC is affiliated with the University of South Florida and university appointments are available, as applicable, and academic faculty rank in the Department of Immunology at Moffitt is commensurate with qualifications and experience.

In summary, this position offers an exciting opportunity to build upon and enhance Moffitt's significant cellular therapy capabilities, accelerating scientific discovery and translation to the clinic, as a contributing leader within one of the most important core facilities at Moffit. *MCC leadership has a clear goal of being a Top 5 Cancer Center in the US by 2028 or sooner*. Moffitt's pursuit of curing cancer with personalized oncology is heavily dependent on the success and growth of cellular therapies, which touches many of the clinical disease-specific pathways that have been established at Moffitt.

For confidential inquires, contact Jay Torio, Senior Director, Department of Academics at Merritt Hawkins: jay.torio@merritthawkins.com